Remus Pharmaceuticals Ltd Financials
Company Logo

Remus Pharmaceuticals Ltd Financial Statement

Remus Pharmaceuticals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

No Data Available

Remus Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Total Revenue Annual79.16
Operating Expenses Annual53.18
Operating Profit Annual28.89
Interest Annual0.38
Depreciation1.19
Net Profit Annual19.90
Tax Annual6.74

Remus Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Cash Flow at the Beginning1.71
Cash Flow from Operations15.59
Cash Flow from Investing-12.42
Cash Flow from Financing-1.42
Cash Flow at the End3.46

Remus Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
PBDIT Margin (%)36.50
PBIT Margin (%)34.13
PBT Margin (%)-55.70
Net PROFIT Margin (%)25.14
Return On Networth / Equity (%)10.06
Return On Networth /Employed (%)13.33
Return On Assets (%)9.80
Total Debt / Equity (X)0.02
Asset Turnover Ratio (%)0.39

Remus Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Fixed Assets Annual7.07
Total Current Assets Annual53.91
Non Current Assets Annual226.40
Total Shareholders Funds Annual242.22
Total Assets Annual280.31

Remus Pharmaceuticals Ltd Earning Calls

No Data Availabe

FAQS on Remus Pharmaceuticals Ltd Financials

As of Oct 6, 2025, Remus Pharmaceuticals Ltd has a market capitalization of 1,319.19 Cr. Value Research classifies it as a Small-Cap company.

Yes, Remus Pharmaceuticals Ltd is with a debt-to-equity ratio of 0.02.

In FY 2024 , Remus Pharmaceuticals Ltd recorded a total revenue of approximately 79.16 Cr marking a significant milestone in the company's financial performance.

Remus Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately Infinity% and 0.3% annually, respectively..

Remus Pharmaceuticals Ltd's current PE ratio is 66.29.

Remus Pharmaceuticals Ltd's ROCE averaged 22.8% from the FY ending March 2023 to 2025, with a median of 14.4%. It peaked at 43.0% in March 2023, reflecting strong capital efficiency over the period..

Remus Pharmaceuticals Ltd's latest EBIT is Rs. 27.02 Cr, surpassing the average EBIT of Rs. 20.45 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions